Novartis Reports Q2 Sales Growth as Newer Medicines Offset Generic Competition
Novartis AG (NYSE:NVS) reported a 3% increase in second-quarter sales to $14.41 billion, driven by strong performance from newer medicines like Kisqali and Kesimpta that offset declines due to generic competition. The company reaffirmed its full-year outlook despite challenges in profitability.
Tickers: $NVS
Topics: generic_competition new_products pharmaceuticals sales_growth